Podcast Episodes
Back to Search
Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer
Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025
1 year ago
Episode 443: ESMO 2025 Bladder Cancer Preview
Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin
1 year ago
Episode 441: The History of IO in Urothelial Cancer - Part 2
Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer
1 year ago
Episode 440: The History of IO in Urothelial Cancer - Part 1
Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer
1 year, 1 month ago
Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer
Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate can…
1 year, 1 month ago
Episode 438: The History of Testis Cancer Treatment
Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.
1 year, 1 month ago
Episode 437: Uromigos Japan - バルバーサ (Erdafitinib)を実臨床でどう使うか！
Erdafitinibがついに承認されましたが、依然として多くのCQが残されています。日常診療に役立つ最新のデータをもとに、その活用法についてディスカッションしました。
1 year, 1 month ago
Episode 436: The History of IO in RCC - Part 2
We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.
1 year, 2 months ago
Episode 435: The History of IO in RCC - Part 1
The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.
1 year, 2 months ago
Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC
Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.
1 year, 2 months ago